Reviewing Rosetta Genomics (ROSG) & Its Competitors
Rosetta Genomics (NASDAQ: ROSG) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Rosetta Genomics to related businesses based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation.
Earnings and Valuation
This table compares Rosetta Genomics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Rosetta Genomics||$9.23 million||-$16.23 million||-0.08|
|Rosetta Genomics Competitors||$215.30 million||-$39.34 million||-68.60|
Rosetta Genomics’ rivals have higher revenue, but lower earnings than Rosetta Genomics. Rosetta Genomics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent recommendations for Rosetta Genomics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rosetta Genomics Competitors||509||2387||6589||122||2.66|
Rosetta Genomics currently has a consensus target price of $3.50, suggesting a potential upside of 386.11%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.00%. Given Rosetta Genomics’ stronger consensus rating and higher probable upside, research analysts plainly believe Rosetta Genomics is more favorable than its rivals.
Risk and Volatility
Rosetta Genomics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Rosetta Genomics’ rivals have a beta of 1.50, suggesting that their average stock price is 50% more volatile than the S&P 500.
This table compares Rosetta Genomics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rosetta Genomics Competitors||-3,342.65%||-534.49%||-40.74%|
Insider and Institutional Ownership
8.3% of Rosetta Genomics shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Rosetta Genomics beats its rivals on 7 of the 12 factors compared.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Receive News & Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.